October 05, 2020 04:13 ET | Source: Immunophotonics, Inc. BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) — Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board of Directors.
“Dr. Knowles has made instrumental contributions in developing and commercializing multiple drugs in several therapeutic areas. His insights will be invaluable in advancing IP-001 through clinical development and commercialization,” stated Dr. Bobby W. Sandage, Jr., Immunophotonics’ Chairman of the Board. IP-001 is the company’s lead asset in clinical development.
Lu Alleruzzo, CEO of Immunophotonics, is honored to welcome the new Board member and commented “I truly look forward to working closely with Dr. Knowles to advance our programs, leveraging his strategic, operational and scientific know-how as we continue to validate the science behind IP-001’s immune-modulating properties.”
Dr. Knowles has reached the pinnacle of achievement academically and implemented his learnings in the pharmaceutical industry with a proven track record of advancing scientific innovation through clinical development and global adoption. In his opinion, “Immunophotonics has a unique and innovative approach to treating serious cancers through immune stimulation. The early data look very interesting and the drug has the potential to help many patients with metastatic cancer who are eligible for ablation or radiation therapy. I look forward to interacting more closely with the excellent scientists in the company going forward.”
To read more, click here.